Osteoporosis International

, Volume 16, Issue 12, pp 1809–1814 | Cite as

Bone mineral density in men with genetic hemochromatosis and HFE gene mutation

  • P. Guggenbuhl
  • Y. Deugnier
  • J. F. Boisdet
  • Y. Rolland
  • A. Perdriger
  • Y. Pawlotsky
  • G. Chalès
Original Article


Genetic hemochromatosis (GH) is an iron overload disorder mainly due to the C282Y mutation of the HFE gene. The possibility of bone involvement was only recently recognized. The aims of this study were to assess bone mineral density (BMD) and bone remodeling in men with GH, and to examine the influence of iron overload. Thirty-eight men (mean age 47.2±9.4 years) with well-defined HFE-related GH were studied. They had an important iron overload with liver iron concentration to age ratio >2.5, no previous venesection therapy and were C282Y homozygotes ( n =37) or compound C282Y/H63D heterozygote ( n =1). BMD measured by DXA was 0.925±0.15 g/cm2 at the lumbar spine (LS) and 0.778±0.13 g/cm2 at the femoral neck (FN). Osteopenia (T-score <−1 SD) was observed in 78.9% of patients and osteoporosis (T-score <−2.5 SD) in 34.2%. Vitamin D levels were normal, and no 1–84 parathyroid hormone dysfunction was found. Hypogonadism was found in only 13.2% of patients. Patients with hypogonadism had lower LS BMD than eugonadal patients (0.788±0.16 and 0.954±0.14 g/cm2). Bone remodeling and parathyroid hormone levels were lower in patients with cirrhosis, but BMD values were similar to those in patients without cirrhosis. FN BMD appeared to fall with rising hepatic iron concentrations ( r =−0.399). We conclude that there is significant bone loss in HFE-related hemochromatosis that cannot solely be explained by hypogonadism or cirrhosis. Further investigations are needed to determine the role of iron overload itself.


Bone mineral density Hemochromatosis Iron overload Osteopenia Osteoporosis 


  1. 1.
    Yaouanq J, Feingold J, Lacombe D (1999) Hémochromatose. Ann Genet 42:234–240PubMedGoogle Scholar
  2. 2.
    Feder JN, Gnirke A, Thomas W, Tshuchihashi Z, Ruddy DA, Basava A, Dormishian F, Domingo R Jr, Ellis MC, Fullan A, Hinton LM, Jones NL, Kimmel BE, Kronmal GS, Lauer P, Lee VK, Loeb DB, Mapa FA, McClelland E, Meyer NC, Mintier GA, Moeller N, Moore T, Morikang E, Prass CE, Quintana L, Starnes SM, Schatzman RC, Brunke KJ, Drayna DT, Risch NJ, Bacon BR, Wolff RK (1996) A novel MHC class-I like gene is mutated in patients with hereditary haemochromatosis. Nat Genet 13:399–408CrossRefPubMedGoogle Scholar
  3. 3.
    Bridle KR, Frazer DM, Wilkins SJ, Dixon JL, Purdie DM, Crawford DH, Subramaniam VN, Powell LW, Anderson GJ, Ramm GA (2003) Disrupted hepcidin regulation in HFE-associated haemochromatosis and the liver as a regulator of body iron homeostasis. Lancet 361:699–673CrossRefGoogle Scholar
  4. 4.
    Jouanolle AM, Gandon G, Jezequel P, Blayau M, Campion ML, Yaouanq J, Mosser J, Fergelot P, Chauvel B, Bouric P, Carn G, Andrieux N, Gicquel I, Le Gall JY, David V (1996) Haemochromatosis and HLA-H. Nat Genet 13:251–252CrossRefGoogle Scholar
  5. 5.
    Brissot P, Troadec MB, Loreal O (2004) The clinical relevance of new insights in iron transport and metabolism. Curr Hematol Rep 3:107–115PubMedGoogle Scholar
  6. 6.
    Delbarre F (1960) L’ostéoporose des hémochromatoses. Sem Hop Paris 36:3279–3295PubMedGoogle Scholar
  7. 7.
    Pawlotsky Y, Lancien G, Roudier G, Hany Y, Louboutin JY, Ferrand B, Bourel M (1979) Histomorphométrie osseuse et manifestations ostéo-articulaires de l’hémochromatose idiopathique. Rev Rhum Mal Osteoartic 46:91–99PubMedGoogle Scholar
  8. 8.
    Pawlotsky Y, Le Dantec P, Moirand R, Guggenbuhl P, Jouanolle AM, Catheline M, Meadeb J, Brissot P, Deugnier Y, Chalès G (1999) Elevated parathyroid hormone 44–68 and osteoarticular changes in patients with genetic hemochromatosis. Arthritis Rheum 42:799–806CrossRefPubMedGoogle Scholar
  9. 9.
    Sinigaglia L, Fargion S, Fracanzani AL, Binelli L, Battafarano N, Varenna M, Piperno A, Fiorelli G (1997) Bone and joint involvement in genetic hemochromatosis: role of cirrhosis and iron overload. J Rheumatol 24:1809–1813Google Scholar
  10. 10.
    Diamond T, Stiel D, Posen S (1989) Osteoporosis in hemochromatosis: iron excess, gonadal deficiency, or other factors? Ann Intern Med 110:430–436PubMedGoogle Scholar
  11. 11.
    Bisbocci D, Marinone C, Ballanti P, Villata E, Suriano A, Vallauri P, Chiandussi L (1991) Bone involvement in primary hemochromatosis : osteoporosis and hormonal bone pattern in hemochromatosis. In: Gentilini P, Dianzani MU (eds) Experimental and clinical hepatology. Elsevier, London, pp 163–169Google Scholar
  12. 12.
    Chalès G, Guggenbuhl P (2003) When and how should we screen for hereditary hemochromatosis? Joint Bone Spine 70:263–270CrossRefPubMedGoogle Scholar
  13. 13.
    Barry M, Sherlock S (1971) Measurement of liver-iron concentration in needle-biopsy specimens. Lancet 328:100–103CrossRefGoogle Scholar
  14. 14.
    Gandon Y, Guyader D, Heautot JF, Reda MI, Yaouanq J, Buhe T, Brissot P, Carsin M, Deugnier Y (1994) Hemochromatosis : diagnosis and quantification of liver iron with gradient-echo MR imaging. Radiology 193:533–538PubMedGoogle Scholar
  15. 15.
    Gandon Y, Olivié D, Guyader D, Aubée C, Oberti F, Sebille V, Deugnier Y (2004) Non-invasive assessment of hepatic iron stores by MRI. Lancet 363:357–362CrossRefPubMedGoogle Scholar
  16. 16.
    Guyader D, Jacquelinet C, Moirand R, Turlin B, Mendler MH, Chaperon J, David V, Brissot P, Adams P, Deugnier Y (1998) Noninvasive prediction of fibrosis in C282Y homozygous hemochromatosis. Gastroenterology 115:929–936PubMedGoogle Scholar
  17. 17.
    Kanis JA, Melton LJ, Christiansen C, Johnston CC, Khaltaev N (1994) The diagnosis of osteoporosis. J Bone Miner Res 9:1137–1141PubMedGoogle Scholar
  18. 18.
    Conte D, Caraceni M, Duriez J, Mandelli C, Corghi E, Cesana M, Ortolani S, Bianchi PA (1989) Bone involvement in primary hemochromatosis and alcoholic cirrhosis. Am J Gastroenterol 84:1231–1234PubMedGoogle Scholar
  19. 19.
    Pawlotsky Y, Roussey M, Hany Y, Simon M, Bourel M (1974) Hyperparathormonémie dans l’hémochromatose idiopathique. Nouv Presse Med 3:1757–1758PubMedGoogle Scholar
  20. 20.
    Audran M, Chappard D, Legrand E, Libouban H, Baslé MF (2001) Bone microarchitecture and bone fragility in men: DXA and histomorphometry in humans and in the orchidectomized rat model. Calcif Tissue Int 69:214–217CrossRefPubMedGoogle Scholar
  21. 21.
    De Vernejoul MC, Pointillart A, Cywiner- Golenzer C, Morieux C, Bielakoff J, Modrowski D, Miravet L (1984) Effects of iron overload on bone remodelling pigs. Am J Pathol 116:377–384PubMedGoogle Scholar
  22. 22.
    Ebina Y, Okada S, Hamazaki S, Toda Y, Midorikawa O (1991) Impairment of bone formation with aluminium and ferric nitriloacetate complexes. Calcif Tissue Int 48:28–36PubMedGoogle Scholar
  23. 23.
    Guanabens N, Parés A, Alvarez L, Martinez de Osaba MJ, Monegal A, Peris P, Ballesta AM, Rodes J (1998) Collagen-related markers of bone turnover reflect the severity of liver fibrosis in patients with primary biliary cirrhosis. J Bone Miner Res 13:731–738PubMedGoogle Scholar
  24. 24.
    Chales G, Guggenbuhl P (2001) Ostéoporose de l’hémochromatose génétique. Rev Rhum [Ed Fr] 68:749–751Google Scholar
  25. 25.
    Diamond T, Pojer R, Alfrey A, Posen S (1991) Does iron affect osteoblast function ? Studies in vitro and in patients with chronic liver disease. Calcif Tissue Int 48:373–379PubMedGoogle Scholar
  26. 26.
    Diamond T, Stiel D, Lunzer M, McDowall D, Eckstein R, Posen S (1989) Hepatic osteodystrophy. Gastroenterology 96:213–221PubMedGoogle Scholar

Copyright information

© International Osteoporosis Foundation and National Osteoporosis Foundation 2005

Authors and Affiliations

  • P. Guggenbuhl
    • 1
  • Y. Deugnier
    • 2
  • J. F. Boisdet
    • 1
  • Y. Rolland
    • 3
  • A. Perdriger
    • 1
  • Y. Pawlotsky
    • 1
  • G. Chalès
    • 1
  1. 1.Rheumatology DepartmentUniversity HospitalRennesFrance
  2. 2.Hepatology DepartmentUniversity HospitalRennesFrance
  3. 3.Radiology DepartmentUniversity HospitalRennesFrance

Personalised recommendations